comparing data for capecitabine after neoadjuvant chemotherapy in tnbc
Published 5 years ago • 1.2K plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
4:28
for residual tnbc post-chemo, capecitabine should be offered
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
4:01
capecitabine remains the adjuvant standard of care for tnbc with residual disease | ingrid mayer
-
23:39
educational sessions: "io vs capecitabine for tnbc"
-
3:12
triple-negative breast cancer: selecting chemotherapy
-
1:10
comparing 3 types of targeted therapies for triple-negative breast cancer
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
6:54
no pcr in patients after neoadjuvant chemotherapy in tnbc
-
1:17
neoadjuvant immunotherapy in tnbc and targeted lnd in breast cancer: 2023 best of breast conference
-
1:25
dr. goetz on adjuvant capecitabine following neoadjuvant chemotherapy and surgery
-
8:22
the immune landscape of residual tnbc after neoadjuvant chemotherapy
-
3:27
her2 de novo mbc: neratinib vs lapatinib plus capecitabine
-
1:31
results for neratinib plus capecitabine in her2 breast cancer brain metastases
-
33:30
neelima denduluri, md -- treatment of triple negative breast cancer
-
47:29
optimizing therapy in her2 disease with dr. reshma mahtani
-
2:13
dr. edith perez on study 301 that compared eribulin to capecitabine in mbc
-
1:27
what to do in patients with early-stage tnbc who have not achieved a pcr?
-
14:24
adjuvant capecitabine did not significantly improve outcomes for early-stage tnbc
-
5:54
case 3: treatment after progression in triple-negative breast cancer